Your browser doesn't support javascript.
loading
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Breyer, Johannes; Eckstein, Markus; Sikic, Danijel; Wezel, Felix; Roghmann, Florian; Brehmer, Mirco; Wirtz, Ralph M; Jarczyk, Jonas; Erben, Philipp; Bahlinger, Veronika; Goldschmidt, Franziska; Fechner, Guido; Chen, Jack; Paxinos, Ellen; Bates, Michael; Haas, Maximilian; Zengerling, Friedemann; Bolenz, Christian; Burger, Maximilian; Hartmann, Arndt; Kriegmair, Maximilian C.
Afiliación
  • Breyer J; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de.
  • Eckstein M; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. johannes.breyer@ukr.de.
  • Sikic D; Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Wezel F; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Roghmann F; Department of Urology and Pediatric Urology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Brehmer M; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Wirtz RM; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany.
  • Jarczyk J; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Erben P; Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany.
  • Bahlinger V; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Goldschmidt F; Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany.
  • Fechner G; Stratifyer Molecular Pathology GmbH, Cologne, Germany.
  • Chen J; Institute of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany.
  • Paxinos E; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Bates M; Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Haas M; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Zengerling F; Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Bolenz C; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Burger M; Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Hartmann A; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
  • Kriegmair MC; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
Sci Rep ; 13(1): 15437, 2023 09 18.
Article en En | MEDLINE | ID: mdl-37723173
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido